All stories tagged :

People

Hyaluronic Acid Based Dermal Fillers Market Analysis Report 2025: Influencers Normalize...

admin
People

FuelPositive: First Scalable Green Ammonia Production System Successfully Installed on Manitoba...

admin
People

Introducing The Pop Fund: Making Fundraising Effortless and Delicious

admin
People

I Fund Cities Announces Monthly Webinar Series Featuring Expert Insights from...

admin
People

Well+Good and Philips Sonicare Team Up for Self-Care Switch Up to...

admin
People

Huge Unveils the Next Wave of Intelligent Experiences

admin
People

LGI Homes Introduces Eagle Landing, A Brand-New Community in Tacoma, Washington

admin
People

Bread Financial™ Signs Long-Term Agreement to Provide Dual Credit Card Program...

admin
People

FG Communities Acquires Manufactured Housing Community in Franklin, North Carolina

admin
People

[Latest] Global Candle Market Size/Share Worth USD 23,381.3 Million by 2033...

admin
People

Lifelong Labs’ Greg Lindberg Shares Key Strategies for Staying Motivated in...

admin

Featured

Pr Newswire

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a...

admin
Pr Newswire

Indaptus Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate...

admin
Pr Newswire

BetterLife Pharma Provides Scientific Update of Mechanism of Action of BETR-001...

admin
Pr Newswire

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

admin
admin

Aprea Therapeutics Reports First Quarter 2025 Financial Results and Provides a...

ATRN-119, our ATR inhibitor, exhibits early evidence of single agent, anti-tumor activity and is progressing toward the recommended Phase 2 dose (RP2D) in the ongoing ABOYA-119 clinical trial Three patients in the 550 mg twice daily cohort in the ongoing...